broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K38527262-300-01-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.634363 | -0.295691 | -0.112156 | 0.866777 | 0.008083 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000996 |
BRD-K38852836-001-02-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.183008 | 0.571513 | 0.480073 | 0.560663 | 0.012908 | 0.028653 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000996 |
BRD-K39974922-001-04-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.293121 | 1.18832 | 0.16866 | 1 | 0.042027 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000996 |
BRD-K41859756-001-06-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.323994 | 7.664788 | 0.710671 | 0.557621 | 0.004373 | 0.005011 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000996 |
BRD-K42495768-001-01-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.807746 | 0.797512 | 0.029894 | 0.969818 | 3.382239 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000996 |
BRD-K42805893-001-04-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.288255 | 4.579246 | 0.254939 | 0.901549 | 2.61346 | 3.152921 | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000996 |
BRD-K42828737-001-03-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.986524 | 0.17896 | -0.007777 | 0.99431 | 0.501991 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000996 |
BRD-K42898655-001-01-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.46536 | 0.594264 | 0.265234 | 0.69705 | 0.002362 | 0.210972 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000996 |
BRD-K43389675-001-02-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.133282 | 2.941621 | 0.519196 | 0.71799 | 0.425262 | 0.472534 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000996 |
BRD-K44227013-001-06-4 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.714896 | 2.224148 | 0.162594 | 0.868512 | 0.113824 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000996 |
BRD-K44408410-001-17-6 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.295667 | -2.586812 | 0.063095 | 0.975939 | 0.000687 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000996 |
BRD-K44827188-001-06-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.081299 | 0.182558 | -0.070544 | 1 | 0.013099 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000996 |
BRD-K46386702-001-02-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.925245 | 0.708146 | 0.019465 | 0.946596 | 0.007958 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000996 |
BRD-K49350383-001-14-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.093392 | -0.094941 | -0.126061 | 1 | 0.132786 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000996 |
BRD-K50010139-001-01-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.412577 | 0.272257 | -0.039264 | 0.764118 | 0.414804 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000996 |
BRD-K50168500-001-07-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.50862 | 0.795965 | 0.35742 | 0.897495 | 1.742092 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000996 |
BRD-K51313569-001-07-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.414621 | 2.010157 | 0.358042 | 1 | 0.257919 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000996 |
BRD-K51791723-003-01-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.607852 | 0.241567 | 0.040809 | 0.769606 | 0.015358 | null | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000996 |
BRD-K51967704-001-03-6 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.45053 | 8.759083 | 0.633752 | 0.801514 | 0.300283 | 0.391052 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000996 |
BRD-K53414658-001-08-2 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.879872 | 1.0457 | 0.009746 | 0.894544 | 0.001439 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000996 |
BRD-K54256913-001-08-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.127752 | 6.031162 | 0.441865 | 0.832748 | 1.555405 | 1.633369 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000996 |
BRD-K54955827-001-02-2 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.718703 | 0.088998 | 0.014739 | 0.846669 | 0.009922 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000996 |
BRD-K54997624-001-06-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.122592 | -0.105953 | -0.033751 | 1 | 163.154074 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000996 |
BRD-K55187425-236-05-2 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.292284 | 3.105146 | 0.58986 | 0.533552 | 0.016678 | 0.022132 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000996 |
BRD-K56343971-001-14-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.903963 | -6.372739 | -0.078884 | 0.951213 | 0.084408 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000996 |
BRD-K56981171-001-02-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.688282 | -0.272973 | -0.09258 | 0.900028 | 0.003444 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000996 |
BRD-K57080016-001-15-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.719247 | -4.306224 | 0.418606 | 0.954683 | 0.002921 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000996 |
BRD-K57169635-001-04-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.350926 | 0.54583 | 0.428823 | 0.659536 | 0.059353 | 0.544905 | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000996 |
BRD-K58435339-001-03-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.304639 | 0.808869 | 0.765277 | 0.613186 | 0.044217 | 0.141305 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000996 |
BRD-K58529924-001-01-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.671144 | 0.469456 | -0.114692 | 0.876043 | 0.366392 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000996 |
BRD-K58550667-001-08-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.479834 | -0.441837 | 0.008292 | 1 | 0.000003 | null | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000996 |
BRD-K59317601-001-05-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.196816 | 0.489208 | 0.765715 | 0.550686 | 0.038895 | 0.108146 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000996 |
BRD-K59369769-001-22-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.815902 | -4.447711 | -0.017369 | 0.868483 | 0.62551 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000996 |
BRD-K60866521-001-07-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.009586 | -0.072055 | -0.135922 | 1 | 0.870503 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000996 |
BRD-K60997853-001-02-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.896978 | -3.528142 | -0.013591 | 0.98187 | 0.003363 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000996 |
BRD-K62008436-001-23-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.169892 | 1.850328 | 0.590859 | 0.550686 | 0.003269 | 0.004091 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000996 |
BRD-K62196610-001-01-6 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.983481 | 0.125303 | -0.033813 | 0.989864 | 0.001746 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000996 |
BRD-K62200014-003-10-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.940171 | 0.265268 | -0.125749 | 0.95055 | 0.000113 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000996 |
BRD-K62391742-001-09-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.748505 | 2.344183 | -0.007494 | 0.788452 | 0.002817 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000996 |
BRD-K62627508-001-01-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.872328 | -0.953547 | -0.26305 | 0.976837 | 0.002859 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000996 |
BRD-K63504947-001-14-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.356943 | -0.019903 | -0.08609 | 1 | 0.103285 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000996 |
BRD-K63712959-001-01-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.012282 | -0.152714 | -0.037511 | 1 | 0.286666 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000996 |
BRD-K64052750-001-22-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.76669 | 3.239581 | -0.073025 | 0.859089 | 0.028477 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000996 |
BRD-K64881305-001-03-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.378042 | 0.731369 | 0.416987 | 0.537814 | 0.005841 | 0.040208 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000996 |
BRD-K66175015-001-12-4 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | -0.24841 | 0.374554 | 0.44019 | 0.602367 | 0.984416 | 0.335353 | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000996 |
BRD-K69694239-001-02-2 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.197366 | 4.806966 | 0.623442 | 0.639429 | 0.127827 | 0.141902 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000996 |
BRD-K69776681-001-03-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.648545 | 3.446047 | 0.010938 | 0.673206 | 0.001171 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000996 |
BRD-K70301465-001-05-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.575651 | 4.959105 | 0.431406 | 0.686724 | 0.007736 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000996 |
BRD-K73838513-003-05-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.826215 | -1.346123 | 0.025039 | 0.979717 | 0.001578 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000996 |
BRD-K74514084-003-09-2 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.001489 | -0.139073 | -0.024358 | 1 | 3,047.746566 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000996 |
BRD-K75009076-001-02-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.574371 | 0.008412 | -0.006567 | 0.784172 | 0.002693 | null | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000996 |
BRD-K76210423-001-01-6 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.965996 | -0.23729 | -0.135827 | 0.980751 | 0.270083 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000996 |
BRD-K76239644-001-02-6 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.580985 | 1.405027 | 0.102741 | 0.850783 | 0.3173 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000996 |
BRD-K76674262-001-03-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.12772 | 8.9721 | 0.833302 | 0.475381 | 0.029185 | 0.03016 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000996 |
BRD-K76908866-001-07-6 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.053043 | -0.023913 | -0.023086 | 1 | 0.000057 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000996 |
BRD-K77625799-001-07-7 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.52325 | 7.725545 | 0.340449 | 0.913409 | 1.715921 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000996 |
BRD-K78431006-001-15-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.906561 | -0.197344 | -0.020044 | 0.949112 | 0.206984 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000996 |
BRD-K79254416-001-21-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.463587 | 3.795769 | 0.410864 | 0.844876 | 0.604182 | 1.204766 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000996 |
BRD-K81016934-001-02-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.420148 | 0.508939 | -0.125532 | 0.84051 | 1.175369 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000996 |
BRD-K81418486-001-44-2 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 2.158643 | 1.169408 | 0.515954 | 1 | 0.998797 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000996 |
BRD-K81473043-001-19-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.169212 | 0.810238 | -0.024621 | 1 | 0.000824 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000996 |
BRD-K82135108-001-04-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 2.364082 | -2.115965 | 0.002691 | 1 | 0.000283 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000996 |
BRD-K82746043-001-19-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.479427 | 0.207021 | 0.182956 | 0.761612 | 0.188662 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000996 |
BRD-K83029223-001-01-3 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.239726 | 1.483233 | 0.727298 | 0.52729 | 0.001493 | 0.002318 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000996 |
BRD-K83988098-001-02-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.263144 | 0.898544 | 0.292325 | 0.746734 | 0.005858 | 0.013454 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000996 |
BRD-K85402309-043-01-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | -0.856087 | 0.59185 | 0.040139 | 0.859486 | 27.680319 | 5.128971 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000996 |
BRD-K85606544-001-09-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.605467 | 0.128249 | 0.035836 | 0.771311 | 0.005889 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000996 |
BRD-K86118762-001-01-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.271924 | -0.008622 | -0.067961 | 1 | 0.146464 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000996 |
BRD-K86972824-001-01-4 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.913792 | 1.002484 | 0.025953 | 0.94064 | 0.011939 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000996 |
BRD-K87737963-001-06-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.027284 | -0.212193 | -0.127251 | 1 | 1.68535 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000996 |
BRD-K87909389-003-03-4 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.214369 | 4.996304 | 0.543237 | 0.755184 | 0.486002 | 0.543646 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000996 |
BRD-K88510285-001-17-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.161455 | 0.991557 | 0.376034 | 0.582339 | 0.019932 | 0.029535 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000996 |
BRD-K92441787-001-04-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.662111 | -4.914231 | 0.373893 | 0.855841 | 0.038327 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000996 |
BRD-K92723993-001-17-4 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 6.740226 | 0.503126 | 0.027353 | 1 | 22,982.717289 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000996 |
BRD-K95142244-001-01-5 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.200201 | -0.080663 | -0.128091 | 1 | 0.023528 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000996 |
BRD-K96123349-236-02-8 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.763776 | -0.428143 | -0.049669 | 0.968213 | 0.000332 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000996 |
BRD-K98572433-001-02-9 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.248403 | 0.431132 | 0.249175 | 0.719191 | 0.385495 | 1.895992 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000996 |
BRD-K99113996-001-02-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.278975 | 4.012509 | 0.701375 | 0.777085 | 0.497712 | 0.610006 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000996 |
BRD-K99616396-001-05-1 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.986228 | -0.107533 | -0.003922 | 0.990734 | 73.796663 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000996 |
BRD-K99749624-001-07-0 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 1.193126 | -0.149821 | -0.028298 | 1 | 41.359274 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000996 |
BRD-M97302542-001-04-4 | ACH-000996 | HEC251_ENDOMETRIUM | MTS010 | 1 | 0.785381 | 5.804249 | 0.131328 | 0.889328 | 0.067085 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000996 |
BRD-A25234499-001-19-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.001737 | 0.232708 | -0.130701 | 1 | 0.034424 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000997 |
BRD-A74914197-001-02-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.51361 | 1.64808 | 0.478026 | 0.792478 | 0.009949 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000997 |
BRD-K02130563-001-11-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.099117 | -0.338605 | -0.053529 | 1 | 0.005888 | null | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000997 |
BRD-K03390685-001-01-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 3.204801 | 0.810476 | 0.756739 | 1 | 0.325278 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000997 |
BRD-K03406345-001-21-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.484083 | 0.558422 | 0.040054 | 1 | 3.21967 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000997 |
BRD-K03449891-001-08-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.781428 | -0.007802 | -0.022874 | 0.879592 | 18,312,327,953.066902 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000997 |
BRD-K03765900-001-01-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.607104 | 1.121497 | -0.111505 | 1 | 11,146.171769 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000997 |
BRD-K05804044-001-18-5 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 2.426668 | 0.643624 | 0.604877 | 1 | 3.817445 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000997 |
BRD-K06814349-304-02-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.214126 | 1.087663 | 0.563289 | 0.762322 | 0.551851 | 0.922687 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000997 |
BRD-K08109215-001-06-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.858786 | 0.313965 | 0.003636 | 0.905824 | 0.005767 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000997 |
BRD-K08542803-001-02-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.038028 | 1.360557 | 0.710557 | 0.728679 | 0.659233 | 0.698699 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000997 |
BRD-K08547377-001-04-4 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.286522 | 5.884776 | 0.700222 | 0.66778 | 0.10902 | 0.125984 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000997 |
BRD-K08703257-001-13-9 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.276684 | 0.248144 | 0.028397 | 1 | 1.868983 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000997 |
BRD-K08799216-001-05-3 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.264984 | 0.702696 | -0.117895 | 1 | 0.73701 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000997 |
BRD-K09951645-001-11-8 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.403093 | 0.237754 | 0.101719 | 1 | 0.17383 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000997 |
BRD-K11267252-001-05-1 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 1.188004 | 2.074469 | 0.05699 | 1 | 0.239884 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000997 |
BRD-K11630072-001-13-2 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.431276 | 17.287944 | 0.467822 | 0.974208 | 6.439853 | 7.223124 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000997 |
BRD-K12184916-001-19-6 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 0.712843 | 0.54901 | 0.041179 | 0.752037 | 0.000683 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000997 |
BRD-K12343256-001-14-7 | ACH-000997 | HCT15_LARGE_INTESTINE | MTS010 | 1 | 3.415803 | 0.496083 | 0.806835 | 1 | 0.601201 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000997 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.